Amneal Pharmaceuticals, Inc.

AMRX

US03168L1052

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
7.6 ^USD	+2.98%		+11.60%	+25.21%

09/07	Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant	CI
01/07	Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments	MT

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year Ended December 31, 2023

January 10, 2024 at 05:34 pm IST

Amneal Pharmaceuticals, Inc. reaffirmed earnings guidance for the year ended December 31, 2023. For the year, the company expects Net revenue to be $2.37 billion - $2.42 billion.

Latest news about Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant	10/07	CI
Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments	01/07	MT
Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar	01/07	CI
Kashiv Biosciences Enters into Exclusive Licensing Agreement with Amneal Pharmaceuticals, Inc. for Commercialization of A Proposed Biosimilar to XOLAIR®	01/07	CI
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 3000 Growth Index	01/07	CI
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 3000E Growth Index	01/07	CI
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Growth Index	01/07	CI
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2500 Growth Index	01/07	CI
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell Small Cap Comp Growth Index	01/07	CI
Transcript : Amneal Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 01:30 PM	05/06
Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies	05/06	CI
Amneal Pharmaceuticals Begins Supplying Generic Version of Narcan	23/05	DJ
Amneal Begins Supplying Over-The-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California	23/05	CI
Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $8 From $6.25, Maintains Buy Rating	06/05	MT
Truist Securities Raises Amneal Pharmaceuticals' Price Target to $9 From $7, Maintains Buy Rating	03/05	MT
Drugmaker Amneal agrees to $270 million U.S. opioid settlement	03/05	RE
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	03/05	MT
Transcript : Amneal Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 03, 2024	03/05
Amneal Pharmaceuticals Q1 Adjusted Earnings, Revenue Climb	03/05	MT
(AMRX) AMNEAL PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $0.53 - $0.63	03/05	MT
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Reports Q1 Revenue $659.2M, vs. Street Est of $619M	03/05	MT
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Posts Q1 EPS $0.14, vs. Street Est of $0.09	03/05	MT
North American Morning Briefing : Apple, Amgen -2-	03/05	DJ
Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for Full Year 2024	03/05	CI
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI

Chart Amneal Pharmaceuticals, Inc.

Duration

Period

More charts

Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Companyâs Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segmentâs portfolio includes central nervous system disorders (Parkinsonâs disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Companyâs AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.

Sector

Pharmaceuticals

Calendar

09/08/2024 - Q2 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Amneal Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.6 USD

Average target price

8.25 USD

Spread / Average Target

+8.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AMNEAL PHARMACEUTICALS, INC.	+25.21%	2.28B
ELI LILLY AND COMPANY	+61.53%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.66%	359B
MERCK & CO., INC.	+15.06%	325B
ABBVIE INC.	+9.18%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.67%	177B
PFIZER, INC.	+2.47%	165B

Other Pharmaceuticals